Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.09+0.01 (+0.93%)
Close on Nov 13, 2026Market cap $4.82MP/E –Yield –
Skye Bioscience cash
Cash and short-term investments held at the end of each period.
Skye Bioscience's cash was $4.82M at Sep 30, 2026. For fiscal 2025 it was $25.74M, down 62.4% from the year before. Over ten years it grew 23.1% a year on average. The highest annual figure on record is $68.42M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.74M | -62.4% |
| FY2024 | Dec 31, 2024 | $68.42M | +561.9% |
| FY2023 | Dec 31, 2023 | $10.34M | +39899.4% |
| FY2022 | Dec 31, 2022 | $25.84K | -99.7% |
| FY2021 | Dec 31, 2021 | $8.99M | +263.3% |
| FY2020 | Dec 31, 2020 | $2.47M | +34.9% |
| FY2019 | Dec 31, 2019 | $1.83M | -1.3% |
| FY2018 | Dec 31, 2018 | $1.86M | +602.7% |
| FY2017 | Dec 31, 2017 | $264.38K | +158.4% |
| FY2016 | Dec 31, 2016 | $102.32K | -96.8% |
| FY2015 | Dec 31, 2015 | $3.22M | +6072.6% |
| FY2013 | Oct 31, 2013 | $52.19K | +97.6% |
| FY2012 | Oct 31, 2012 | $26.40K | +89.8% |
| FY2011 | Oct 31, 2011 | $13.91K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.82M | -86.4% |
| Q2 FY2026 | Jun 30, 2026 | $10.06M | -79.3% |
| Q1 FY2026 | Mar 31, 2026 | $17.11M | -71.1% |
| Q4 FY2025 | Dec 31, 2025 | $25.74M | -62.4% |
| Q3 FY2025 | Sep 30, 2025 | $35.31M | -47.6% |
| Q2 FY2025 | Jun 30, 2025 | $48.59M | -34.5% |
| Q1 FY2025 | Mar 31, 2025 | $59.22M | -28.9% |
| Q4 FY2024 | Dec 31, 2024 | $68.42M | +561.9% |
| Q3 FY2024 | Sep 30, 2024 | $67.41M | – |
| Q2 FY2024 | Jun 30, 2024 | $74.12M | +13292.7% |
| Q1 FY2024 | Mar 31, 2024 | $83.34M | +3023.0% |
| Q4 FY2023 | Dec 31, 2023 | $10.34M | +39899.4% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $553.44K | -81.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.67M | -55.6% |
| Q4 FY2022 | Dec 31, 2022 | $25.84K | -99.7% |
| Q3 FY2022 | Sep 30, 2022 | $415.39K | -96.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.93M | -43.5% |
| Q1 FY2022 | Mar 31, 2022 | $6.01M | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | $8.99M | +263.3% |
| Q3 FY2021 | Sep 30, 2021 | $11.09M | +162.5% |
| Q2 FY2021 | Jun 30, 2021 | $5.19M | +4958.7% |
| Q1 FY2021 | Mar 31, 2021 | $5.15M | +813.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.47M | +34.9% |
| Q3 FY2020 | Sep 30, 2020 | $4.22M | +219.1% |
| Q2 FY2020 | Jun 30, 2020 | $102.52K | -96.4% |
| Q1 FY2020 | Mar 31, 2020 | $563.86K | -87.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.83M | -1.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.32M | +24.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.81M | +49.7% |
| Q1 FY2019 | Mar 31, 2019 | $4.42M | +49.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.86M | +602.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.06M | +2190.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.88M | +1184.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.95M | +606.1% |
| Q4 FY2017 | Dec 31, 2017 | $264.38K | +158.4% |
| Q3 FY2017 | Sep 30, 2017 | $46.41K | – |
| Q2 FY2017 | Jun 30, 2017 | $146.36K | – |
| Q1 FY2017 | Mar 31, 2017 | $417.77K | – |
| Q4 FY2016 | Dec 31, 2016 | $102.32K | – |
See a number that looks wrong?